GRTX News and Press, Galera Therapeutics Inc. From 11/14/23

2023-11-14 08:51:41 ET More on Galera Therapeutics Galera plunges after citing risks to business continuity Seeking Alpha’s Quant Rating on Galera Therapeutics Historical earnings data for Galera Therapeutics Financial information for Galera Therapeuti...

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Galera Therapeutics Inc. (GRTX) is expected to report $-0.44 for Q3 2023

2023-10-31 13:29:52 ET Nano-cap biotech Galera Therapeutics ( NASDAQ: GRTX ) lost more than half of its value on Tuesday after announcing that the company will be forced to discontinue operations if it fails to find strategic alternatives. The warnings come after an FDA Type A m...

FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2...

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announce...

MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announce...

2023-08-14 09:48:53 ET Galera Therapeutics press release ( NASDAQ: GRTX ): Q2 GAAP EPS of -$0.48. As of June 30, 2023, Galera had cash, cash equivalents and short-term investments of $38.8 million. For further details see: Galera Therapeutics GAAP EPS of -$0.48

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in workforce FDA granted orphan drug designation to rucosopasem for the...